A new pill form of GLP-1 is making the weight loss drug more accessible As a new pill form of the weight loss drug hits the market, we are with one of the patients who took part in the Wegovy pill clinical trial
The manufacturer, Eli Lilly Co., has submitted orforglipron to the FDA for approval for use in weight management, with a decision expected in the second quarter of 2026
Vomiting and diarrhea might accompany nausea for some individuals, causing discomfort but often manageable with dose adjustments
Of note, a recent meta-analysis encompassing those clinical trials focused on the cardiovascular safety of GLP-1 RAs found significant reductions in MACE3 (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), hospitalization for heart failure and progression of chronic kidney disease [8]
This issue troubled scientists for years
Now rebranded as the Ozempic pill, the updated formulation is available in different strengths of 1.5 mg, 4 mg, and 9 mg
